What is the connection between Parkinson Disease (PD) and schizophrenia from a neurotransmitter perspective?
Responses to classmates must consist of at least 271 words (not including the greeting and the references), do NOT repeat the same thing your classmate is saying, try to add something of value like a resource, educational information to give to patients, possible bad outcomes associated with the medicines discussed in the case, try to include a sample case you’ve seen at work and discuss how you feel about how that case was handled. Try to use supportive information such as current Tx guidelines, current research related to the treatment, anything that will enhance learning in the online classroom. Hello Class, Scenario 2: (Antiparkinsonian Drugs) What is the connection between Parkinson Disease (PD) and schizophrenia from a neurotransmitter perspective ( Keltner & Steele, 2018, p. 129) ? To explain the relationship between Parkinson Disease (PD) and schizophrenia it is important to understand how PD effects an individual’s neurotransmitters. As explained in Keltner and Steele’s writing (2018), PD is characterized by the imbalance between acetylcholine and dopamine within the brain. PD symptoms are associated with a lack of dopamine and subsequent increase in acetylcholine (Keltner & Steele, 2018). While PD is explained by a lack of dopamine, schizophrenia is explained by an increase of dopamine resulting in the positive symptoms associated with the disease (Keltner & Steele, 2018). Gupta et al. (2018) explain it best by stating “pharmacological medications and response in Parkinson’s disease and schizophrenia revolve around the levels of dopamine in brain.” The treatment for each disease is essentially targeting a decrease of dopamine excretion and reuptake in schizophrenia patients, and an increase in PD patients (Gupta et al., 2018). Due to neurotransmitters effected in each disease and subsequent treatment options, a patient’s symptoms may appear similar. Best Regards, Erin Thomson References Gupta, A. K., Rani, K., Swarnkar, S., Kumar, G. K., Khan, M. I., Pokhriyal, R., … Hariprasad, G. (2018). Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson’s disease: A Preliminary Study. Journal of Central Nervous System Disease, (10), 1. https://doi-org.prx-keiser.lirn.net/10.1177/1179573518803585 Keltner, N.L. & Steele, D. (2018). Psychiatric nursing, (8th ed.). St. Louis, MO. Mosby.